Plitidepsin

Search with Google Search with Bing

Information
Drug Name
Plitidepsin
Description
Entry(CIViC)
CIViC
[No Data.]
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Plitidepsin has a dual effect on the human SK-MEL-... HDAC9 HDAC9 EXPRESSION Sensitivity true MMMP detail
Plitidepsin has a dual effect on the human SK-MEL-... MAPK8 MAPK8 UNDEREXPRESSION Resitance or Non-Reponse true MMMP detail
Plitidepsin (a marine depsipeptide) is a HDAC inhi... HDAC9 HDAC9 UNKNOWN Resitance or Non-Reponse true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT02100657 Completed Phase 1 Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma June 2014 June 2018
NCT01102426 Completed Phase 3 Aplidin - Dexamethasone in Relapsed/Refractory Myeloma June 2010 November 2017
NCT00229203 Completed Phase 2 A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma February 2005 August 2008
NCT03117361 Terminated Phase 2 Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide May 8, 2017 July 30, 2018
NCT04784559 Terminated Phase 3 Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection June 4, 2021 March 1, 2023
NCT05705167 Terminated Phase 2 Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care April 19, 2023 April 19, 2024
NCT01876043 Terminated Phase 2 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial February 2012 April 2015
NCT03070964 Terminated Phase 2 A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma October 25, 2016 July 2018